Treatment strategies underpinning the global programme to eliminate lymphatic filariasis

Gyapong, J O and Kumaraswami, V and Biswas, G and Ottesen, E A (2005) Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opinion on Pharmacotherapy, 6 (2). pp. 179-200. ISSN Print: 1465-6566; Online: 1744-7666

PDF 200558.pdf - Published Version Restricted to Registered users only Download (332kB) | Request a copy

Abstract

Lymphatic filariasis (LF) is a disease targeted for elimination. The global strategy is a once-yearly, single-dose, two-drug regimen utilized by communities at risk for LF, with the goal of reaching 80% population coverage yearly, for at least 5 years, in order to interrupt transmission of LF. Where onchocerciasis is co-endemic, the regimen is ivermectin 200 – 400 mg/kg plus albendazole 400 mg; elsewhere, the regimen should be diethylcarbamazine 6 mg/kg plus albendazole 400 mg. This paper reviews in detail the evidence for the efficacy and safety of these two-drug regimens underpinning the global strategy and makes recommendations for future developments in chemotherapy for LF, focusing on unresolved issues. These include optimal frequency, duration and end point of treatment, tools for monitoring successful therapy and means for detecting the potential development of resistance to any of the trhee antifilarial drugs on which the Global Programme to Elinminate LF depends.

Item Type:	Article
Uncontrolled Keywords:	albendazole, combination treatment, diethylcarbamazine, ivermectin, lymphatic filariasis
Subjects:	Filariasis
Divisions:	Clinical Research
Depositing User:	Dr. Rathinasabapati R
Date Deposited:	29 Nov 2013 06:32
Last Modified:	09 Mar 2016 07:04
URI:	http://eprints.nirt.res.in/id/eprint/735

Actions (login required)

View Item